Yuan Zhi
Stock Analyst at B. Riley Securities
(4.54)
# 1,109
Out of 4,396 analysts
126
Total ratings
38.8%
Success rate
22.4%
Average return
Main Sectors:
Stocks Rated by Yuan Zhi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Rated: Buy | $21 → $35 | $31.56 | +10.90% | 7 | Jun 9, 2026 | |
| HYPR Hyperfine | Rated: Buy | $1.6 → $2 | $1.42 | +40.85% | 8 | May 13, 2026 | |
| RDNT RadNet | Rated: Buy | $87 → $83 | $56.18 | +47.74% | 6 | May 1, 2026 | |
| LNTH Lantheus Holdings | Rated: Buy | $84 → $97 | $99.98 | -2.98% | 25 | May 1, 2026 | |
| SRTA Strata Critical Medical | Initiated Coverage: Buy | $8 | $5.61 | +42.60% | 1 | Mar 25, 2026 | |
| CATX Perspective Therapeutics | Rated: Buy | $11 → $13 | $3.00 | +333.33% | 13 | Mar 18, 2026 | |
| FHTX Foghorn Therapeutics | Maintained: Buy | $10 | $3.87 | +158.40% | 2 | Dec 17, 2025 | |
| RADX Radiopharm Theranostics | Maintained: Buy | $13 → $16 | $4.25 | +276.47% | 6 | Dec 16, 2025 | |
| MIR Mirion Technologies | Maintained: Buy | $22 → $29 | $17.00 | +70.59% | 9 | Oct 28, 2025 | |
| TOI The Oncology Institute | Maintained: Buy | $6 | $4.96 | +20.97% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 → $3 | $0.4225 | n/a | 3 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16 → $2 | $1.01 | n/a | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $19 → $15 | $15.19 | n/a | 14 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $79 | $22.72 | n/a | 12 | Feb 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $34 | $27.55 | n/a | 5 | Jan 9, 2023 |
Tango Therapeutics
Jun 9, 2026
Rated: Buy
Price Target: $21 → $35
Current: $31.56
Upside: +10.90%
Hyperfine
May 13, 2026
Rated: Buy
Price Target: $1.6 → $2
Current: $1.42
Upside: +40.85%
RadNet
May 1, 2026
Rated: Buy
Price Target: $87 → $83
Current: $56.18
Upside: +47.74%
Lantheus Holdings
May 1, 2026
Rated: Buy
Price Target: $84 → $97
Current: $99.98
Upside: -2.98%
Strata Critical Medical
Mar 25, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $5.61
Upside: +42.60%
Perspective Therapeutics
Mar 18, 2026
Rated: Buy
Price Target: $11 → $13
Current: $3.00
Upside: +333.33%
Foghorn Therapeutics
Dec 17, 2025
Maintained: Buy
Price Target: $10
Current: $3.87
Upside: +158.40%
Radiopharm Theranostics
Dec 16, 2025
Maintained: Buy
Price Target: $13 → $16
Current: $4.25
Upside: +276.47%
Mirion Technologies
Oct 28, 2025
Maintained: Buy
Price Target: $22 → $29
Current: $17.00
Upside: +70.59%
The Oncology Institute
Sep 5, 2025
Maintained: Buy
Price Target: $6
Current: $4.96
Upside: +20.97%
Oct 2, 2024
Reiterated: Buy
Price Target: $4 → $3
Current: $0.4225
Upside: n/a
Aug 7, 2024
Downgraded: Hold
Price Target: $16 → $2
Current: $1.01
Upside: n/a
Jul 30, 2024
Upgraded: Buy
Price Target: $19 → $15
Current: $15.19
Upside: n/a
Feb 7, 2024
Reiterated: Buy
Price Target: $79
Current: $22.72
Upside: n/a
Jan 9, 2023
Maintained: Buy
Price Target: $34
Current: $27.55
Upside: n/a